Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19341977 | 0.80 | SMPD3 (0.39) | AXLL3MBTL1NUDT1 | |
| SCHEMBL10282570 | 0.80 | L3MBTL1 (0.41) | AXLL3MBTL1PIK3CG | |
| SCHEMBL104733 | 0.80 | AXL (0.39) | AXLL3MBTL1 | |
| Hydrochloric Acid SCHEMBL139076 | 0.79 | AXL (0.38) | AXLL3MBTL1 | |
| SCHEMBL14890721 | 0.74 | SYK (0.47) | AXLL3MBTL1 | |
| SCHEMBL17447664 | 0.70 | CYP19A1 (0.35) | AXLL3MBTL1 | |
| SCHEMBL457296 | 0.67 | TRPM5 (0.32) | — | |
| SCHEMBL23994426 | 0.65 | ALDH1A1 (0.37) | — | |
| SCHEMBL4560704 | 0.64 | DYRK1A (0.52) | — | |
| Hydrochloric Acid SCHEMBL2420306 | 0.63 | L3MBTL1 (0.47) | AXLL3MBTL1HTR2CNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304192-A | Preparation process of 6, 8-dibromoimidazo [1,2-b ] pyridazine | 陕西友帮生物医药科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117304192-B | Preparation process of 6, 8-dibromoimidazo [1,2-b ] pyridazine | 陕西友帮生物医药科技有限公司 | 2026-03-24 | — | — | CN | disclosed |
| CN-117304192-B | Preparation process of 6, 8-dibromoimidazo [1,2-b ] pyridazine | 陕西友帮生物医药科技有限公司 | 2026-03-24 | — | — | CN | disclosed |
| EP-4593958-A1 | NOVEL CDK9 INHIBITORS | Origenis GmbH (DE) | 2025-08-06 | — | — | EP | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2024068740-A1 | NOVEL CDK9 INHIBITORS | ORIGENIS GMBH (DE) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024068740-A1 | NOVEL CDK9 INHIBITORS | ORIGENIS GMBH (DE) | 2024-04-04 | — | — | WO | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-117304192-A | Preparation process of 6, 8-dibromoimidazo [1,2-b ] pyridazine | 陕西友帮生物医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117304192-A | Preparation process of 6, 8-dibromoimidazo [1,2-b ] pyridazine | 陕西友帮生物医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-8324211-B2 | 6-Dimethylamino-2-(2-hydroxymethyl-3-{8-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-imidazo[1,2-b]pyridazin-6-yl }-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; asthma, lupus ; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324211-B2 | 6-Dimethylamino-2-(2-hydroxymethyl-3-{8-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-imidazo[1,2-b]pyridazin-6-yl }-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; asthma, lupus ; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324211-B2 | 6-Dimethylamino-2-(2-hydroxymethyl-3-{8-[5-(morpholine-4-carbonyl)-pyridin-2-ylamino]-imidazo[1,2-b]pyridazin-6-yl }-phenyl)-3,4-dihydro-2H-isoquinolin-1-one; asthma, lupus ; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2012-12-04 | — | — | US | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032031-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-15 | — | — | WO | disclosed |
| EP-2307413-A1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010006947-A1 | NOVEL PHENYL-IMIDAZOPYRIDINES AND PYRIDAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016301-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | AXL 193/4885L3MBTL1 2631/4885HTR2C 2556/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | AXL 2494/4885L3MBTL1 3951/4885HTR2C 1699/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | AXL 2677/4885L3MBTL1 4253/4885HTR2C 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.